Jump to content

Sialyl-Lewis A

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 2a02:1810:251b:4800:1db2:bc81:c5c7:c846 (talk) at 12:31, 24 November 2017 (Added the carbohydrate sequence that defines SLeA and added a link to the relevant chapter in the NCBI book "Essentials for Glycobiology". Moved Lewis A reference from the sentence where it was incorrect, to See also section.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Sialyl-Lewis A
Identifiers
3D model (JSmol)
MeSH sialyl+Lewis+A
  • O=C(O)[C@@]1(O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]3[C@H](O[C@H]4[C@@H](O)[C@H](O)[C@H](O)[C@H](C)O4)[C@@H](CO)OC(O)[C@@H]3NC(C)=O)[C@@H]2O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1
Properties
C31H52N2O23
Molar mass 820.748 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

Sialyl-LewisA, also known as sialyl LeA and SLeA, is a tetrasaccharide carbohydrate with the sequence Neu5Acα2-3Galβ1-3[Fucα1-4]GlcNAcβ- that is usually attached to O-glycans on the surface of cells. It is known to play a vital role in cell-to-cell recognition processes.

Occurrence of the Sialyl-LewisA antigen, detected with the CA19-9 antibody, is highly correlated advanced epithelial cancers, such as stage III and stage IV colorectal cancers.[1]

See also

References

  1. ^ Matsui T, Kojima T, Suzuki H, Hamajima H, Nakazato H, Ito K, Nakao A, Sakamoto J (June 2004). "Sialyl Lewisa Expression as a Predictor of the Prognosis of Colon Carcinoma Patients in a Prospective Randomized Clinical Trial". Japanese Journal of Clinical Oncology. 34 (10): 588–593. doi:10.1093/jjco/hyh110.

Sources

Retrieved from "https://en.wikipedia.org/w/index.php?title=Sialyl-Lewis_A&oldid=811852744"